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Abstract
Obesity is a rising epidemic, and is one of the most common, costly and preventable
health problems the world is experiencing today (Center for Disease Control and Prevention,
[CDC], 2017). From this, it is important to establish an effective treatment plan that can be
implemented across the nation for maximum patient benefit. Lifestyle changes such as diet and
exercise are important to any health care plan and are equally necessary to reduce health risks.
However, in certain patients, lifestyle changes are not enough due to the maladaptive biologic
process in their brain. From this, additional treatment options need to be available to these
patients. This study was a systematic literature review which evaluated studies from CINAHL,
Clinical Key, Cochrane Library, and PubMed to formulate a conclusion. Research focused on
two pharmacotherapy options, phentermine and orlistat, in addition to two surgical options,
gastric bypass and sleeve gastrectomy, for added weight loss treatment when compared to
lifestyle alone. Both medical therapies, pharmacological and surgical, were found to be
beneficial in augmenting lifestyle changes in multiple studies. Therefore, concluding that
pharmacologic and surgical therapies are valid options in resistant obesity treatment in addition
to lifestyle changes such as diet and exercise.
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Obesity: Modern Medicine vs. Lifestyle
Adulthood obesity is one of the most common, costly and preventable diseases the world
is experiencing today (Center for Disease Control and Prevention, [CDC], 2017). While obesity
can be related to socioeconomic status and race, it is ultimately nondiscriminatory. Roughly 40%
of Americans were obese as of 2016, whereas only 30% were in 2000 (National Center for
Health Statistics, [NCHS], 2017). A 10% increase does not seem astronomical, but 10% of the
US population is 32.57 million. So, in 16 years there were 32.57 million more Americans
diagnosed with obesity. The purpose of this study is to determine the most effective treatment
method available today to combat this rising epidemic.
Statement of the Problem
Obesity has a multitude of comorbidities associated with it such as: HTN,
hyperlipidemia, diabetes mellitus type 2, stroke, coronary artery disease, depression and others,
including death. Therefore, it is important to evaluate studies regarding each treatment method’s
effectiveness and long-term outcomes to better assess where more research should take place.
Research Questions
In obese populations, Body Mass Index (BMI) greater than or equal to 30, do drug
therapies, such as phentermine and orlistat, provide better long-term health outcomes than
lifestyle changes to diet and exercise patterns?
In obese populations, BMI greater than or equal to 30, do surgeries, such as gastric
bypass and sleeve gastrectomy (SG), provide better long-term health outcomes than lifestyle
changes to diet and exercise patterns?
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Methodology
The research performed to answer the above research questions included databases:
CINAHL, Clinical Key, Cochrane Library, and PubMed. Active research took place between
August 2018 and January 2019. From the previously listed databases, over 400,000 articles were
found when “obesity” was searched. Therefore, a more descriptive search was needed to yield a
more realistic research field. Thus, key words such as: “phentermine” yielded 2902 articles,
“orlistat” 5270, “sleeve gastrectomy” 14101, “RYGB” 18241, and “obesity and lifestyle” 41469.
Only clinical trials, comparative studies, meta-analysis, randomized controlled trials and
systemic reviews originally written in the English language that were available to UND for free
were used in this paper. Sources were excluded that evaluated multiple forms of weight loss
surgery without separating out resulting statistics, as the scope of this research is specific to
RYGB and sleeve gastrectomy. Research on which weight loss surgery was superior was also
not analyzed. For the pharmacologic searches, sources were excluded when the drug was
evaluated with respect to an individual disease, and not overall patient wellbeing or when the
drug efficacy was tested with another medication. Additional lifestyle sources were not included
as the lifestyle changes were made specific to one disease, and not an overall improvement in
patient wellbeing. For populations of study, any research that involved juveniles was excluded,
this allowed more focus on the adult population. The majority of resources used came from
PubMed. The search history for PubMed used key words such as: "Bariatric Surgery/adverse
effects"[Majr], "Gastric Bypass/adverse effects"[Mesh] OR "Gastric
Bypass/complications"[Mesh], "Obesity Management/adverse effects"[Majr] OR "Obesity
Management/complications"[Majr] OR "Obesity Management/mortality"[Majr] OR "Obesity
Management/pharmacology"[Majr], and "Obesity/diet therapy"[Majr] OR
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"Obesity/surgery"[Majr]. From "Gastric Bypass/adverse effects"[Mesh] OR "Gastric
Bypass/complications"[Mesh]. Review of the Endoscopic Treatment of Weight Regain
Following Roux-en-Y Gastric Bypass: a Systematic Review and Meta-analysis also took place.
However, this source was ultimately not used as treating post-operative weight regain was not a
field being evaluated. Yet, Endoscopic Treatment of Weight Regain Following Roux-en-Y
Gastric Bypass: a Systematic Review and Meta-analysis had two sources, number 4 and 55 that
contributed important information and their studies were included. “New treatment modalities
for obesity” was also searched on PubMed. The article Healthy Weight and Obesity Prevention:
JACC Health Promotion Series was viewed and the source list was searched for phentermine
which yielded the Gadde et all, 2011 source. Additional key words searched in PubMed include:
“Gastric bypass”, “Lifestyle changes for obesity and chronic disease”, “Orlistat“, “Phentermine
and obesity”, “Sleeve gastrectomy in obese patients”. On the CINAHL database, I searched
“Phentermine”, “Orlistat”, “Sleeve gastrectomy in obesity”, and “Obesity lifestyle”. On Clinical
Key the keyword searched was “Healthy lifestyle”, whereas on Cochrane Library the keyword
used was“Obesity lifestyle”. From these searches, various inclusion/exclusion criteria were
weighed and articles were further evaluated resulting in the below review of literature.
Anticipated Results
In the treatment of obese patients, it is anticipated that while drug therapy and surgery
options allow for quicker results, these patients will most likely have decreased long term
success in the ability to maintain weight loss and in the prevention of obesity related
comorbidities. It is anticipated that lifestyle changes will show a more stable BMI change with a
decrease in development of obesity related comorbidities. Ultimately, the anticipation is that in
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addition to modern medical therapies, lifestyle changes are needed for any obese patient to be
successful in weight loss and reduction of comorbidities long term.
Review of Literature
A review of the recent literature shows that there are two main drug therapies in obese
patients: a phentermine and topiramate combination, or orlistat. The phentermine-topiramate
combination is a stimulant like sympathomimetic amine, where orlistat is a peripherally acting
pancreatic lipase inhibitor that reduces the absorption of fat by interfering with triglyceride
breakdown in the intestine. The review of literature also shows that there are two main surgeries
for weight loss: gastric bypass and sleeve gastrectomy. In gastric bypass, the stomach is
bypassed completely, whereas in a sleeve gastrectomy, the stomach size is reduced. Current
literature shows that weight loss efforts involving any of the previously listed methods results in
a larger total weight loss, when compared to diet and exercise alone. Therefore, it would seem as
though modern medical therapies are superior to lifestyle changes alone.
What is phentermine-topiramate.
Kushner (2018) wrote an article about the different weight loss strategies in obesity
management. From this, evaluation of phentermine – topiramate as pharmacotherapy in the
treatment of obesity took place. This was not a study and was written based on known data,
therefore no limitations or strengths were obtained.
According to Kushner (2018), the Food and Drug Administration (FDA) approved
pharmacologic treatment of all obese patients with a BMI ≥ 30 kg/m2 or ≥27 kg/m2 if the
patient’s health status was complicated by an obesity related comorbidity. Phenterminetopiramate, approved for adjunct therapy in 2012, is a sympathomimetic amine that works as a
stimulant anorectic (Kushner, 2018). The base structure of the drug is amphetamine β-
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phenylethylamine, with the side chain modified to reduce excessive stimulation properties and
therefore the likelihood of addiction (Kushner, 2018). Phentermine-topiramate has been shown
to promote greater weight loss when used in conjunction with lifestyle changes than lifestyle
changes alone (Kushner, 2018). Six randomized trials showed that when patients used
phentermine-topiramate they lost an average of 1.3 - 13.2 pounds of additional weight when
compared to lifestyle changes alone during a 2-24-week period (Kushner, 2018).
While these studies may show that phentermine-topiramate is an effective medication to
adjunct weight loss efforts, it is known to have some moderate side effects, such as: restlessness,
insomnia, dry mouth, constipation, increased blood pressure and heart rate (Kushner, 2018).
Therefore, evaluation of side effects in addition to medication weight loss response should be
performed 12 weeks after starting treatment. Post hoc observed trial data has shown that
phentermine-topiramate is less successful with patients who did not show early results with
weight loss (Kushner, 2018). Thus, early evaluation is key in determining the need for a higher
dose or drug discontinuation.
Phentermine-topiramate safety and effects.
Gadde et al. (2011) of the Obesity Clinical Trial Programme and The Collaboration on
Neuroimmunology: Question, Understand, Educate, Restore (CONQUER) study performed a
randomized, double blind, placebo controlled study in 93 centers in the US. One limitation to this
study was that 31% of participants were lost for endpoint assessment follow up, from this three
different methods were used to analyze the data. All of which yielded similar results.
Additionally, 86% of the participants where Caucasian and 70% were female, and thus the
population demographics were skewed. The population of study was 2485, and this results in a
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strength of data. Also, due to the design of the study many of the patients had comorbidities,
including psychiatric, and therefore weight loss effect on comorbidities could be established.
The goal of Gadde et al. (2011) was to evaluate the effect of phentermine-topiramate in
two different doses on weight loss when taken once a day over 56 weeks. Participants had to be
18-70 years old, have a BMI of 27-45 kg/m2, and meet the various inclusion/exclusion criteria
(Gadde et al., 2011). Once chosen, the study participants were stratified based on sex and status
as diabetic or prediabetic, then randomly assigned into a treatment option based on a 2:1:2 ratio
(Gadde et al., 2011). Treatment options included placebo (n=993), phentermine 7.5 mg
topiramate 46 mg (n=498), and phentermine 15 mg topiramate 92 mg (n=994) (Gadde et al.,
2011). All patients received drug titration, if not in the placebo group, during the first four weeks
of the study, starting at phentermine 3.75 mg and topiramate 23 mg (Gadde et al., 2011). Drug
doses were then maintained for the following 52 weeks. The ratios used were unequal to better
visualize the benefits and risks or higher doses of the combination drug.
All participants were given standardized counseling for diet and lifestyle modification
and this was followed up on during monthly visits (Gadde et al., 2011). During the visits,
patients were also evaluated on their progress by obtaining body weight, blood pressure, heart
rate, waist circumference, clinical and laboratory variables, concomitant drugs, adverse events,
and treatment compliance (Gadde et al., 2011). A patient health questionnaire (PHQ-9) and
Columbia Suicide Severity Rating Scale (C-SSRS) were also performed to evaluate mental
health status and a referral was given when indicated (Gadde et al., 2011).
Sensitivity analysis was performed on all participants in the study, with an additional
analysis of only patients who completed the study (Gadde et al., 2011). This data was analyzed
via the analysis of covariance (ANCOVA) model. Safety analysis was performed with Fisher’s
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exact test with 2 x 2 contingency tables based on number of adverse events, laboratory
assessments, vital signs, ECG, physical examination, and PHQ-9 and C-SSRS scores (Gadde et
al., 2011).
Exact patient demographics and study outcomes can be visualized on pages 48 and 49
with figure “Effects of phentermine plus topiramate on body weight” and tables “Demographic
and baseline characteristics of patients” and “Changes from baseline to week 56 in secondary
endpoints”. Ultimately phentermine-topiramate combinations show a greater efficacy than
placebo. However when comparing the two phentermine-topiramate combinations, the
phentermine 15 mg topiramate 92 mg had more reported adverse effects (5%) in addition to their
greater body weight reduction (–10.2 kg absolute change, –9·8% least square mean [95% CI –
10.4 to –9.3]; –8·6% difference [–9.3 to –8.0]; p<0·0001) than the phentermine 7.5 mg
topiramate 46 mg dose with a 3% adverse effect and a body weight reduction of (–8.1 kg
absolute change, –7·8% least squares mean [95% CI –8.5 to –7.1]; difference –6·6% [–7.4 to –
5.8]; p<0·0001) (Gadde et al., 2011). No suicide attempts were recorded with any of the three
possible trials (Gadde et al., 2011).
Kolotkin, Gadde, Peterson, and Crosby (2015) performed a meta-analysis with
randomized, placebo-controlled trials lasting 56 weeks to establish if phentermine and topiramate
combination drug therapy results in improvements of health-related quality of life (HRQOL) or
if HRQOL improvements are related to weight loss alone. A limitation to Kolotkin et al. (2015)
is that only 4 variables were tested in the cause of weight loss and there may be a number of
others that would significantly affect weight loss. Additionally, patients were excluded based on
a PHQ-9 score of greater than 10 and a blood pressure reading of >140/90 (Kolotkin et al.,
2015). With these exclusions it is difficult to adequately evaluate the mediating effect these
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variables have. Kolotkin et al. (2015) was able to use obesity specific and HRQOL measures as
well as multiple mediation analysis to appraise the goal of this study. This analysis resulted in
statistically significant evidence with a large population of study, contributing to the universality
of its findings.
Kolotkin et al. (2015) took participants from Evaluation and Quality Improvement
Program. (EQUIP) (n=751) and Collaboration on Neuroimmunology: Question, Understand,
Educate, Restore (CONQUER) (n=1623) studies. The impact of weight on quality of life
(IWQOL-Lite), medical outcomes study short form health survey (SF-36) and PHQ-9 were used
to evaluate if phentermine with topiramate combination drug therapy results in improvements of
health-related quality of life (HRQOL) or if HRQOL improvements are related to weight loss
alone (Kolotkin et al., 2015).
Participant inclusion and exclusion criteria was varied. Specifically, exclusion was based
on significant depression present at screening (PHQ-9 score >10), history of bipolar disorder or
psychosis, more than one lifetime episode of major depression, presence or history of suicidal
ideation, and current antidepressant use not stable for the last 3 months (Kolotkin et al., 2015).
Multiple mediation analyses via Participant Responsibility Openness Commitment
Experimentation Sensitivity Sense (PROCESS) macro within the Statistical Package for the
Social Sciences (SPSS) version 19.0 were performed to discover if changes to BMI, depressive
symptoms, blood pressure and hemoglobin A1c within 16 weeks led to greater improvements in
HRQOL over the 56 weeks of study (Kolotkin et al., 2015). All analyses were made with
separation of the EQUIP and CONQUER studies (Kolotkin et al., 2015). Moderated mediation
models were then created to evaluate the data and separate results based on age, gender, race,
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baseline triglycerides, baseline waist circumference, history of pain, or self-reported history of
psychiatric illness (Kolotkin et al., 2015).
The results of Kolotkin et al. (2015) study show that phentermine-topiramate
combinations result in greater IWQOL-Lite improvements in both EQUIP R 2 = .417 (p < .0001)
compared to placebo and CONQUER compared to placebo R 2 = .326 (p < .0001). In EQUIP,
IWQOL-Lite improved by 12.9, standard deviation (SD) = 16.4, with drug therapy and 8.2, SD =
15.2, with placebo at the end of the 56-week study (Kolotkin et al., 2015). BMI reduction was
shown to be significant (p<0.0001) (Kolotkin et al., 2015). Emphasizing that weight loss may be
the lone cause for improvement in HRQOL. In CONQUER, IWQOL-Lite improved by 4.5, SD
= 16.2, with drug therapy and 10.0, SD = 14.6, with placebo at the end of the 56-week study. The
BMI and PHQ-9 score showed (p<0.0001) and (p<0.019) respectively. This demonstrated that
BMI reduction and depressive symptom control both improved HRQOL (Kolotkin et al., 2015).
Furthermore, in both trials at the end of the 56 weeks there were improvements in HRQOL
(p<0.0001) (Kolotkin et al., 2015). Both trials also showed that phentermine with topiramate
combination pharmacotherapy result in greater HRQOL improvements than placebo.
Moldovan et al. (2016) performed a 12-week randomized, double blind, placebo
controlled clinical trial was performed to evaluate phentermine 37.5 mg per day effect on weight
loss and food cravings. Possible limitations to Moldovan et al. (2016) are the selection bias of the
study. Participants were all within 50 miles of Loma Linda, CA and had computer access.
Additionally, the population of study was 35-70 years old, excluding a large portion of adults age
18-34. Participants were also followed up on by third year pharmacology students, which could
allow for a greater margin of error, in comparison to using certified PharmDs. Another limitation
was the food costs for this study. The costs were waived for these participants but were estimated
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to be about $350.00 a month which is not economically feasible in the entire population.
However, the results of this study were still significant with a good population size. Thus, its
findings cannot be discounted, as part of the general population could afford this treatment
option.
Participants of Moldovan et al. (2016) were all patients of the LLU Center for Health
Promotion and were all enrolled via word of mouth or letter mail. Participants were then
evaluated based on various inclusion and exclusion criteria by a questionnaire (Moldovan et al.,
2016). The population of study was n=77 (Moldovan et al., 2016). Participants were then
randomized into either placebo or phentermine groups in a 1:1 ratio (Moldovan et al., 2016).
All participants were given Medifast meal replacements and instructed to follow the Take
Shape for Life Optimal Weight 5&1 Plan for weight loss and the Habits of Health program
(Moldovan et al., 2016). LLU School of Pharmacy third year students followed up with
participants weekly by answering questions and encouraging lifestyle changes (Moldovan et al.,
2016). Biometric data such as gender, age, height, weight and body composition were gathered at
baseline and after the 12-week trial was completed (Moldovan et al., 2016). Additionally,
information regarding Food Craving Inventory (FCI), General Food Cravings State (G-FCQ-S),
and General Food Cravings Trait (G-FCQ-T) was obtained via questionnaire format at baseline
and after the 12-week trial was completed to better evaluate the effect phentermine had on food
craving control (Moldovan et al., 2016). All of the food craving questionnaires have high internal
consistency with Cronbach's α ranging from 0.90 to 0.95 for FCI, from 0.92 to 0.95 for G-FCQ-S
and 0.95 to 0.97 for G-FCQ-T (Moldovan et al., 2016). No significant differences were noted
between the average participant in the placebo or phentermine group regarding the tested
variables at baseline.
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Using statistical software SPSS version 20.0, data was analyzed, and the normality of the
variables was established via the Kolmogorov-Smirnov test (Moldovan et al., 2016). Results
were summarized with standard deviations for quantitative variables and frequency percentages
for qualitative variables (Moldovan et al., 2016). Data was compared between the placebo and
phentermine groups by two tailed independent samples t-tests, Mann‐Whitney U Tests, and χ2
tests (Moldovan et al., 2016). Ultimately, phentermine yielded greater weight loss and BMI
reduction with 12.1% weight loss when compared to the placebo group with a 8.8% weight loss
(p=0.028) (Moldovan et al., 2016). Specifically, phentermine participants lost 2.1% more fat than
the placebo group (p=0.019) (Moldovan et al., 2016). The p value demonstrated no significant
difference in lean body mass between the groups, (p>0.05) (Moldovan et al., 2016). Overall
efficacy of the two tested groups was considered positive if greater than 5% individual weight
loss was achieved (Moldovan et al., 2016). In the phentermine group 97% of participants
achieved this, compared to 76% in the placebo group χ2 = 7.6 (p= 0.006) (Moldovan et al.,
2016). As for patient responses to the FCI, G‐FCQ‐T, and G‐FCQ‐S, both groups experienced
decreases in cravings (Moldovan et al., 2016). The phentermine group did experience a more
substantial fat and sweet craving decrease (p=0.012 and p=0.038, respectively) (Moldovan et al.,
2016). The statistical analysis also found that there was a positive correlation between weight
loss and food cravings r = 0.332, (p= 0.009) or weight loss and sweet cravings r = 0.412
(p< 0.000), regardless of the participant’s group (Moldovan et al., 2016).
Moldovan et al. (2016) concluded that Medifast MRS alone can contribute to statistically
significant weight loss and decreased food cravings, however these results were augmented when
phentermine was added to the weight loss therapy regimen. When phentermine was added to the
regimen there was one new documented case of hypertension, but the hypertension was
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alleviated when the phentermine dose was tapered (Moldovan et al., 2016). Therefore, Moldovan
et al. (2016) concluded that phentermine is beneficial for promoting weight loss and decreasing
food cravings.
What is orlistat.
Kushner (2018) wrote an article about the different weight loss strategies in obesity
management. From this, evaluation of orlistat as pharmacotherapy in the treatment of obesity
took place. This was not a study and was written based on known data, therefore no limitations
or strengths were obtained.
Orlistat is a synthetic lipase inhibitor made from a hydrogenated derivative of lipostatin
(Kushner, 2018). It works by inhibiting pancreatic, gastric and carboxyl ester lipase, as well as
phospholipase A2, therefore hydrolysis and absorption of 30% of fat ceases (Kushner, 2018).
Orlistat is a prescription medication but is also available in a half a prescription dose over the
counter (OTC) (Kushner, 2018). It was first approved by the FDA in 1999, and only available for
use when used in addition to lifestyle changes (Kushner, 2018). This caveat is now harder to
control with the OTC option (Kushner, 2018).
Less than one percent of orlistat is absorbed into the body and thus there are no systemic
side effects (Kushner, 2018). Side effects are generally related to the drug’s excretion
mechanism of feces (Kushner, 2018). Therefore, oily anal spotting, flatus with discharge, fecal
urgency, oily stool, and increased defecation are noted in 10% of patients (Kushner, 2018).
These side effects are highly related to patient compliance with low fat diet and are experienced
early in drug therapy (Kushner, 2018). As the patient becomes more aware of diet
noncompliance side effects and what is in the food they are eating, these side effects diminish
dye to better adherence to proper diet.

OBESITY: MODERN MEDICINE VS. LIFESTYLE

19

Orlistat safety and effects.
Hollywood and Ogden (2016) performed a qualitative design study using thematic
analysis to evaluate an orlistat support system group known as MAP (Motivation, Advice and
Proactive support). Limitations of this study include the small sample size, the biased patient
demographics (80% are female), and possible interviewer compromisation of the data through
their questioning style. Hollywood and Ogden (2016) had strengths in evaluating patient views
on weight loss with real answers and not simple surveys. From this, Hollywood and Ogden
(2016) were able to reach their goal of assessing the experiences and possible causal relationship
of patients who gained weight by 18 months post orlistat therapy.
Hollywood and Ogden (2016) had ten participants who were studied after 18 months of
previous orlistat drug therapy. The ten participants were chosen as the population of study as
they had gained an average of 14.95 kg while participating in 18 months of orlistat therapy
(Hollywood and Ogden, 2016). Initially, thirteen people involved in MAP were contacted based
on highest weight gain, but only 10 responded (Hollywood and Ogden, 2016). The population
yielded two males, and eight females with a mean age of 51.7 years and SD of 12.4 years
(Hollywood and Ogden, 2016). Average BMI was 40.0 kg/m2 at baseline, with a SD of 7.3
kg/m2 (Hollywood and Ogden, 2016).
Hollywood and Ogden (2016) study’s design used interviews done by the researcher,
which involved four questions: “How did you find taking Xenical, the orlistat brand name, Do
you think it helped you lose weight, Do you intend to take it again in the future, and Do you still
feel like you have a weight problem?” The interviews were recorded and transcribed. An
individual coding sheet was created, and codes were put into a list of themes based on thematic
analysis (Hollywood and Ogden, 2016). These themes from each participant were then used to
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create a thematic map (Hollywood and Ogden, 2016). The thematic map of analysis was refined
until three main themes resulted (Hollywood and Ogden, 2016).
The first theme identified was that the GI side effects of the medication prevented the
population from continuing with drug therapy (Hollywood and Ogden, 2016). The second theme
identified barriers to weight loss which included psychologic, physical, relationships, and
individual physiology (Hollywood and Ogden, 2016). The last theme identified was participant’s
thoughts of failure and continued failure due to factors the individual could not control and
therefore the weight gained was not the participant’s fault (Hollywood and Ogden, 2016). The
evaluation of themes in this study for failed weight loss while on pharmacotherapy ultimately
offers strong evidence as to patient mental health status and the relationship to obesity.
Samp, Al-Tahami, Ariffin, Omar, and Rasool (2015) performed a four month follow up
study regarding a previous 9-month study on the effects of orlistat and sibutramine in the
treatment of cardiovascular disease in obese patients with regular counseling by registered
dieticians. A limitation to Samp et al. (2015) is that they are only evaluating one previous study
and therefore this study suffers the same limitations as the previous on in population selection as
well as a small population. However, several variables were measured and statistically analyzed,
establishing a high level of completeness of participant evaluation.
The scope of this scholarly project is not to evaluate sibutramine and therefore the
participants who were on sibutramine in the previous 9-month study will not be included in this
literature review. In the 9-month study, patients were on orlistat 120 mg three times a day, and
18 agreed to participate in the four-month study follow up (Samp et al., 2015). All participants
were obese according to Asian populations with a BMI >27 kg/m2 (Samp et al., 2015).
Additionally, all were nonsmokers, had a blood pressure of less than 146 over less than 95, had a
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non-diabetic fasting blood sugar, not on routine medications, and had an LDL value of less than
5.0 mmol/L (Samp et al., 2015).
After the original nine month study, anthropometric parameters such as total body
weight, BMI, waist and hip circumference, waist and hip ratio, body composition according to
body and visceral fat percentages, metabolic profiles including lipids, fasting blood sugars,
fasting serum insulin and insulin. Cardiovascular risk factors such as blood pressure and
systemic arterial stiffness and total energy expenditure were measured and then again four
months after cessation of pharmacotherapy (Samp et al., 2015). IBM’ SPSS’ Statistics software
Version 20 was used to statistically analyze the data obtained with a paired t-test used to analyze
change in values, only noting significant change if the p value was less than 0.05. These results
are available on page 50 in table “Study parameters at 9 months treatment with orlistat and
sibutramine, and repeated measurements 4 months after stopping treatments” (Samp et al., 2015).
In the initial nine-month study statistically significant decreases were noted in total body
weight, BMI, waist circumference, body and visceral fat percentage, total cholesterol,
triglyceride, insulin level and insulin resistance (Samp et al., 2015). No change was noted in
energy expenditure (Samp et al., 2015). In the four-month follow up study there was statistically
significant increases and therefore cardiovascular benefit in deterioration in body weight, BMI,
waist circumference, body and visceral fat percentage, triglyceride, and fasting blood sugar, with
a decrease noted in energy expenditure (Samp et al., 2015).
Smith et al. (2012) performed a double blind, randomized, placebo controlled 6-month
research study on one individual patient regarding pharmacological efficacy of 60 mg of orlistat
taken 3 times a day with meals for 6 months with cessation of the medication following the 6
months and a follow up of anthropometric measurements two months post cessation. The goal of
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Smith et al., (2012) study was to address the efficacy of orlistat 60 mg in a 32-year-old, white
Hispanic/Latino, active duty soldier with a BMI of 31.5 kg/m2. The limitations to Smith et al.,
(2012) involve the population of study as there was only one participant and thus limited variety
in the study’s universality. However, because of this the patient’s progress and pharmacotherapy
course was able to be more closely monitored and all complications noted. In addition, his follow
up was 100%, so there is no lost data.
The patient denied taking any medication prior to the study, and other than the orlistat, he
only took a multivitamin once a day during the study (Smith et al., 2012). The patient was
chosen due to failing army body fat guidelines and had to report for mandatory weight
management counseling at an army hospital where participate scouting was being performed
(Smith et al., 2012).
Initially the patient was required to report a food diary to get some baseline
measurements (Smith et al., 2012). He reported a 3 meal a day average with one evening snack
totaling an average of 9209.2 KJ per day. Forty four percent of his total energy came from
carbohydrates, 50% from fat and 16% from protein (Smith et al., 2012). He also recorded his
physical activity averaging 45 minutes of aerobic activity 5 days a week and 30 minutes of
weight training 3 days a week (Smith et al., 2012). Before the patient was allowed to start
orlistat, he had to participate in a one hour registered dietician (RD) taught nutrition class in
addition to a one hour of individual counseling with an RD, and a physical therapist taught
exercise class for an hour (Smith et al., 2012).
Once all the previously listed requirements were completed the patient started the
pharmacotherapy. He received a one-month supply of orlistat to be taken three times a day with
meals and one hour of nutrition educational materials to complete (Smith et al., 2012). After each
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month the patient would return for anthropometric measurements, report adverse effects, and get
a new supply of orlistat (Smith et al., 2012). Adherence to the study’s guideline was evaluated
through pill count and was recorded to be about 69-90% (Smith et al., 2012). The patient
struggled in the first month to take the pill three times a day and usually only remembered to take
it twice a day (Smith et al., 2012). Adverse effects reported in the first month were
diarrhea/liquid stool, fatty/oily stool, fecal urgency with control, and gas with discharge (Smith
et al., 2012). During month two there were no adverse effects reported (Smith et al., 2012). In
month 3 the patient again had mild diarrhea/liquid stool and flatulence (Smith et al., 2012).
Months four and five resulted in severe diarrhea/liquid stool and fatty/oily stool that negatively
affected the patient's life, causing him to miss work (Smith et al., 2012). Month six reported
continued diarrhea/liquid stool, but the severity was down to mild or moderate (Smith et al.,
2012).
At the end of the sixth month the patient had achieved a 12.1% weight loss, a fat mass
loss of 12.9 kg and a BMI of 27.7 kg/m2 (Smith et al., 2012). His lean body mass was stable and
there were no notable changes to his blood lipids, glucose and blood pressure (Smith et al.,
2012). His energy intake was measured by himself, and was 11628.7 KJ per day, with 45% from
carbohydrates, 41% from fat and 14% from protein (Smith et al., 2012). After the study
concluded the patient did not take orlistat again, and he was followed up on two months later
(Smith et al., 2012). He was able to maintain his post pharmacotherapy weight, BMI, and fat
mass (Smith et al., 2012). His average KJ intake per day was evaluated again and found to be
about 2302.3 (Smith et al., 2012). Therefore, this study found that orlistat could be beneficial in
promoting weight loss and leading to sustained weight loss after cessation of treatment (Smith et
al., 2012).
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Van Baal, Van den Berg, Hoogenveen, Vijgen, and Engelfriet (2008) performed a
yearlong study with a target population of Dutch individuals with a BMI equal to 30 kg/m2 or
greater between ages 20 and 70 who were not currently being treated for obesity. Van Baal et al.,
(2008) performed this study to evaluate the effectiveness of a low-calorie diet compared to a
low-calorie diet in combination with orlistat 120 mg taken three times daily. Limitations to this
study include that only three different BMI classes were used to statistically evaluate data and
therefore small differences in weight may have not been accounted for. Additionally, since BMI
was assumed to be a continuous risk factor, the variability in BMI and therefore differences in
relative health risk were not appreciated. Side effects were not reconciled for in this study, as
none affected quality of life. The population of study was large at, 1,138,000, which resulted in
reliable, statistically significant, evidence.
Incremental cost-effectiveness ratios (ICERs) were calculated based on an interval model
of 80 years comparing the two treatment options and the respective treatment costs and savings
due to health benefits (Van Baal et al., 2008). Costs in this study are represented in euro value
according to 2005. Quality adjusted life years (QALYs) or years gained due to weight loss were
also evaluated and calculated by the RIVM (Dutch National Institute for Health and
Environment) Chronic Disease Model (CDM) in respect to obesity related diseases such as
coronary heart disease, stroke, diabetes, osteoarthritis, low back pain and some cancers (Van
Baal et al., 2008). The prevalence of the previously listed obesity related disease was found via
general practitioners’ registrations, national registries, and population surveys (Van Baal et al.,
2008).
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A probabilistic sensitivity analysis model was ran 500 times in addition to a univariate
sensitivity analysis to assess the effect of uncertainty and assumptions (Van Baal et al., 2008).
The ultimate ICER that resulted was €58,800 per QALY gained in the orlistat low calorie diet
combination and an ICER of €17,900 per QALY gained for the sole low-calorie diet (Van Baal
et al., 2008). Therefore, the conclusion of the study was that a low-calorie diet without orlistat is
a more cost-effective weight loss treatment plan than in conjunction with orlistat and thus should
be the initial treatment of choice (Van Baal et al., 2008).
What is gastric bypass.
Billeter (2018) wrote an article about the different weight loss procedures in obesity
management. From this, the evaluation of sleeve gastrectomy in the treatment of obesity took
place. This was not a study and was written based on known data, therefore no limitations or
strengths were obtained.
Roux-en-Y gastric bypass (RYGB), which can be performed laparoscopically using a 3642 French bougie, is one of the two most common weight loss surgeries, the other being a sleeve
gastrectomy (Billeter, 2018). In an RYGB the stomach is cut to create a biliopancreatic limb
resulting in roughly 20-30 mL of volume from the stomach’s original 1 L capacity (Billeter,
2018). Within the biliopancreatic limb there is an alimentary limb that is about 120-150 cm in
length and a biliary limb of about 50-100 cm in length, the variation in size is due to surgeons’
individualized technique (Billeter, 2018). Using a stapler and sutures, gastrojejunal and
jejunojejunal anastomosis may also be created (Billeter, 2018).
Gastric bypass safety and effects.
Kofman, Lent, and Swencionis (2010) performed a self-reported internet study evaluating
national web site internet users who had had Roux-en-Y gastric bypass surgery in the last three
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to ten years to establish patient weight outcomes, eating behaviors and perceived quality of life
post gastric surgery. As this is an internet study, Kofman et al. (2010) exclude a possible
population of non-internet users, or individuals who do not have access to the internet.
Additionally, 90% of the population in this study were Caucasian and 96.5% were female. Data
was collected through self-reporting and thus is subject to self-bias and under reporting.
However, the data obtained was statistically significant with a large population of study.
Furthermore, the internet is a large part of society today and less households have a primary
home phone; thus, this could be viewed as a better way to contact individuals for a survey.
Kofman et al. (2010) used various inclusion and exclusion criteria to result in a 497
population of study. The data was collected for the study online by The Questionnaire on Eating
and Weight Patterns Revised (QEWP‐R) to evaluate binge eating disorder diagnosis, and The
Moorehead–Ardelt Quality of Life Questionnaire II (α = 0.84) to establish patient perceived
quality of life (Kofman et al., 2010). The total survey involved 100 questions and could be
completed in less than 15 minutes (Kofman et al., 2010). Multiple demographic information was
also collected such as age, gender, ethnicity, education level, current weight, presurgical weight,
height and total weight loss following surgery (Kofman et al., 2010).
Once collected, data was analyzed by the SPSS 14.0 (SPSS, Chicago, IL). The mean age
of participants was 43.2 years, with 96.5% being female, 90% Caucasian and 70% with some
college education (Kofman et al., 2010). Seventy two percent had surgery between 3 and 5 years
from study data collection date (Kofman et al., 2010). The mean maximum excess weight loss
following surgery was 81% of starting weight, and 97% of participants achieved weight loss of
greater than 50% of starting weight (Kofman et al., 2010). The maximum postsurgical weight
loss occurred at 17.9 months on average following surgery, with weight regain having a
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significant correlation with time since surgery r = 0.192 (p < 0.01) (Kofman et al., 2010). Eighty
seven percent of subjects regained an average of 22.6 pounds, with only 11% of participants
reporting no weight regain after maximum postsurgical weight loss (Kofman et al., 2010).
According to the data a significant relationship was found between participant loss of control
when eating and weight regain r = 0.36 (p< 0.001) (Kofman et al., 2010). Binge eating frequency
was also found to be correlated with weight regain r = 0.24 (p= 0.006) (Kofman et al., 2010).
Additionally, participants reported a negative correlation with health related quality of life and
weight regain r = −0.35 (p< 0.001) (Kofman et al., 2010). Participants diagnosed with binge
eating disorder via the questionnaire also showed poorer quality of life when compared to their
counter parts t[463] = 9.7 (p< 0.001) (Kofman et al., 2010). From statistical analysis, this study
was able to show that while gastric bypass may allow patients to lose weight initially, weight
regain associated with eating patterns may occur and perception of quality of life may not
improve because of this.
Mehaffey et al. (2016) performed a retrospective study over 20 years (1985-2005) at the
University of Virginia, single institution, evaluating the effectiveness of all RYGB surgeries with
10 years post-surgery follow up. As the Mehaffey et al. (2016) study was retrospective,
limitations due to incomplete interval follow up arose. Additionally, outpatient treatments of
complications were difficult to follow, especially before the electronic medical health record.
Furthermore, comorbidities were documented as yes or no, and not in detail according to
treatment plan. From this, there may have been improvements in patient health statuses that were
not documented due to study limitations. Yet, 60% of the large population of study was able to
maintain follow up and statistically significant evidence was obtained. Therefore, this study’s
findings are valuable in establishing RYGB effectiveness.
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The population of study was 1087 with 60% achieving 10 years of follow up (Mehaffey
et al., 2016). All data used for evaluation was obtained by database or telephone and analyzed by
SPSS statistical software to perform a multivariable analysis with statistical significance
calculated using the Student t test (Mehaffey et al., 2016).
RYGB surgeries performed at the date of study were done either by an open or
laparoscopic approach, with open being done more for patients with a statistically significant
larger preoperative BMI (Mehaffey et al., 2016). From the mechanics of how an open RYGB is
performed there are statistically more post-operative incisional hernia rates than with
laparoscopic (16.9% vs 4.7%; p= 0.02) (Mehaffey et al., 2016). However, there was no
significant statistical difference between annual reduction in BMI between the two operations or
reduction in comorbidities being studied (Mehaffey et al., 2016). In general, BMI reduction
peaked at 74% by 24 months and was at 52% at 10 years (both with p< 0.001) (Mehaffey et al.,
2016). In this study there is amelioration of diabetes mellitus after RYGB of 57% at 10 years,
with additional statistically significant reduction in each comorbidity recorded by individual
patients (Mehaffey et al., 2016). Thus, this study found that regardless of open or laparoscopic,
RYGB is a statistically successful method of treatment for obesity related comorbidities when
followed for 10 years post operatively (Mehaffey et al., 2016).
Simonson, Halperin, Foster, Vernon, and Goldfine (2018) performed Sit Less, Interact
Move More Intervention for Type 2 Diabetes Mellitus (SLIMM-T2D), a randomized, parallelgroup clinical trial which elaborated data based on the Consolidated Standards of Reporting
Trials (CONSORT) statement. The goal of Simonson et al. (2018) was to show the effects of
RYGB on type 2 diabetes vs. a multidisciplinary medical management approach. The study is
limited by small sample size, intermediate duration of follow up, using both insulin and oral
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hypoglycemic agent participants, and few cardiovascular events. Simonson et al. (2018) results
contribute to the growing number of small randomized trials, that when evaluated together for
their statistical significance show bariatric surgery is a viable treatment option for diabetics when
no contraindications are noted.
The number of participants involved in the study was 38 after various inclusion and
exclusion criteria (Simonson et al., 2018). Statistical analysis was performed by dichotomous
and continuous variables via logistic regression and longitudinal linear mixed-effects models,
respectively (Simonson et al., 2018). Fixed effects that were defined as categorical were “time”
and “treatment group,” the random effect was “patient,” to create a mixed effects model
(Simonson et al., 2018). Ultimately, at the end of the 3 year study, the RYGB treatment group
showed superior results to the multidisciplinary medical management approach, with increased
weight loss (mean −24.9 kg [95% CI −29.5, −20.4] vs. −5.2 kg [−10.3, −0.2]; p< 0.001) and
lower HbA1c (−1.79% [−2.38, −1.20] vs. −0.39% [−1.06, 0.28] [−19.6 mmol/mol {95% CI
−26.0, −13.1} vs. −4.3 {−11.6, 3.1}]; p < 0.001). In addition, RYGB showed improvements in
coronary heart disease and stroke risk factors (p < 0.05 to p < 0.01) and the impact of weight on
quality of life (p < 0.001) (Simonson et al., 2018). The self-reported short form health outcome
report and the problem areas in diabetes survey did not show a preference to either treatment
being evaluated in this study (Simonson et al., 2018).
From these results, this study was able to conclude that RYGB can benefit patients
dealing with type two diabetes and obesity more than the current multidisciplinary medical
management treatment approach and should therefore be implemented more often in treatment
planning for appropriate patients (Simonson et al., 2018).
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What is sleeve gastrectomy.
Billeter (2018) wrote an article about the different weight loss procedures in obesity
management. From this, evaluation of Roux-en-Y gastric bypass in the treatment of obesity took
place. This was not a study and was written based on known data, therefore no limitations or
strengths were obtained.
A SG is a surgical procedure for weight loss in overweight or obese patients (Billeter,
2018). The SG is done by creating a gastric tube using the stomach by excising and dissecting
the greater curvature patients (Billeter, 2018). The tube is closed by linear staples patients
(Billeter, 2018). Since the stomach is used in the procedure and the length is not decreased, there
tends to be less risk of malnutrition, vitamin deficiency and micronutrient deficiency when
compared with Roux-en-Y where the stomach size is changed dramatically patients (Billeter,
2018).
Sleeve gastrectomy safety and effects.
Blanco, Funes, Giambartolomei, Menzo, Szomstein, and Rosenthal (2018) performed a
retrospective analysis of all bariatric surgeries performed at single institution from 2010 to 2016
to evaluate the effect weight loss surgery has on cardiovascular risk. Unfortunately, 60% of the
patient population was lost to follow up and thus limited conclusion analysis. Additionally, other
variables attributed to cardiovascular risk reduction, such as tobacco cessation and therefore all
results cannot be attributed to weight loss alone. However, the strengths to this study were not
able to be evaluated effectively either, as the Atherosclerotic cardiovascular disease (ASCVD)
and Framingham risk scores (FRS) only indicate presence of disease and not better control or
reduced medication management. Yet, the statistically significant data resulting from the study
and the moderately sized population promote the validity of its results.
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All participants were obtained on an electronic database and various inclusion and
exclusion criteria was applied to result in a population of 360 (Blanco et al., 2018). Specifically,
no patient used in the study had a history of cardiovascular disease such as coronary death,
myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke,
transient ischemic attack, peripheral artery disease, or heart failure (Blanco et al., 2018). ASCVD
and FRS were calculated to find each participant’s 10-year risk of coronary death, nonfatal
myocardial infarction, or fatal/nonfatal stroke (Blanco et al., 2018). Additional data collected
from the participants includes demographics, perioperative parameters and postoperative
outcomes at 12 months (Blanco et al., 2018).
The previously listed data was obtained by patient charts and analyzed by simple linear
regressions and multiple linear regression models to evaluate the effect each parameter had on
patient outcomes at 12 months via statistical software R, version 3.3.1. Chi-square, Fisher exact,
and t tests were also used for statistical evaluation (Blanco et al., 2018). Of the 360 participants,
63.05% had a SG, 20.55% had RYGB and 16.3% had some other form of bariatric surgery
(Blanco et al., 2018). Estimated BMI loss was 66.51% in females and 60.29% in males 12
months post operation (Blanco et al., 2018). For ASCVD risk, female risk dropped by 35.33%
at 12 months post operation and males dropped by 34.73% (Blanco et al., 2018). FRS was
reduced by 32.2% in females and 25.8% in males, 12 months post operation (Blanco et al.,
2018).
From this data, the study was able to conclude that ASCVD and FRS show reduced
values after weight loss surgery (Blanco et al., 2018). Thus, weight loss surgery can help to
reduce patient risk of experiencing a cardiovascular event.

OBESITY: MODERN MEDICINE VS. LIFESTYLE

32

Chopra, Chao, Etkin, Merklinger, Lieb, and Delany (2011) performed a retrospective
review of laparoscopic sleeve gastrectomies performed at Jacobi Medical Center, Bronx, NY
from 2006-2010. The goal of Chopra et al. (2011) was to evaluate if laparoscopic sleeve
gastrectomy could be an effective way of managing obesity in an inner-city population with low
complication rates. The limitations in this study include the population of study, 85.63% were
female, and in the complications described below there is no mention of which patient had what
complication. Therefore, the same patient could have had more than one complication.
Additionally, all of the surgeries reviewed in this study occurred at the same institution and
therefore the complication likelihood is not universal across all institutions. However, there is a
universality to surgical procedures, and it can be assumed that all surgeons would then
experience similar outcomes. Strengths to this study include the size of population as well as the
fact that in all but four participants, this was their first bariatric operation.
The total number of participants included in this study was 185 after various inclusion
and exclusion criteria (Chopra et al., 2011). The data analyzed in this study included BMI,
comorbid conditions, operation time, length of hospital stay, perioperative complications and
resulting weight loss and improvement in comorbidities (Chopra et al., 2011).
The study found that of the 185 participants, 84% found improvement in their diabetic
status, 49.99% had improvement in their hypertension control, 90% had better asthma control,
90.74% found improvements in their obstructive sleep apnea symptoms, and 45.92% had better
control of their gastroesophageal reflux disease (Chopra et al., 2011). The list of complications
experienced perioperatively is as follows: four staple-line leaks, four bleeds, four obstructions,
five vomiting/dehydration, six new onset of GERD symptoms, two with pneumonia, and one
participant with a pulmonary embolism (Chopra et al., 2011). There were no fatalities (Chopra et
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al., 2011). As for management of obesity, the mean excess weight loss at 6 months was 44.76%
from baseline, 55.52% at 12 months, 59.22% at 24 months, 58.92% at 36 months (Chopra et al.,
2011). Yet, thirteen patients experienced an individual weight gain of thirteen pounds throughout
the study length (Chopra et al., 2011).
Foschi et al. (2018) performed a retrospective study from a case-controlled study that
evaluated an ileal interposition with duodenal diversion sleeve gastrectomy (II-DD-SG) to
standard medical care in patients with type two diabetics to see if which treatment plan is
superior. Limitations to Foschi et al. (2018) include that the only contrasting treatment option to
the II-DD-SG was that standard medical care was given, and not intensive. It is possible that
intensive care may have yielded better results when compared to surgery. Additionally, at the
time of study GLP-1 was not available to the patients of study and with the addition of this drug
to a treatment regimen, outcome may have been more favorable. Finally, this study’s population
included relatively young patients with a short diabetic history. This does not discredit the results
of this study for this population, but it does hinder the result’s applicableness to other
populations. The results of this study were statistically significant and valuable as each surgical
participant was matched to a similar non-surgical participant, allowing for the strongest possible
treatment evaluation.
Foschi et al. (2018) used various inclusion and exclusion criteria to obtain a population of
study at the L. Sacco Hospital, Department of General Surgery and Internal Medicine, University
of Milan from 2008-2011. The total population of study was 60, with 30 being surgery
participants and the other 30 being their closest matches available based on patient demographics
(Foschi et al., 2018). For the non-surgical participants, they were treated with a multidisciplinary
team of an endocrinologist, a dietitian and a nurse (Foschi et al., 2018). Both study groups were

OBESITY: MODERN MEDICINE VS. LIFESTYLE

34

evaluated at baseline, and at 1, 3, 6, and 12 months during the first year of the study, then every
six months until the fifth year (Foschi et al., 2018). During each visit anthropometric measures,
glucose metabolism, and cardiovascular risk factors were obtained (Foschi et al., 2018).
To analyze the data obtained, analysis of variance (ANOVA) and Student-t tests were
used, as well as mean values, differences between time points of groups and the Exact Test of
Fisher. For II-DD-SG, mean fasting plasma glucose (FPG) fell from 154.6 ± 6.4 to 89.6 ± 2.4
mg/dL and mean HbA1c from 7.7 ± 0.1% to 5.6 ± 0.2% six months after surgery (Foschi et al.,
2018). These results were stable throughout the five years of the study with p < 0.0001. In 86%
of the surgical patients there was complete diabetic remission, 6.6% had partial remission and
only 6.6% were still considered diabetic (Foschi et al., 2018). At the end of the 5-year study 56%
of surgical patients had remission of cardiovascular risk factors (Foschi et al., 2018). In either
group of study, no statistically significant changes were noted in anthropometric parameters and
lipid metabolism (Foschi et al., 2018). Only two patients in the standard medical care group
achieved complete remission of diabetes (Foschi et al., 2018). Still, in the surgical group
complications were experienced. One participant had sleeve gastrectomy suture line bleeding,
another had an anastomotic leak at the gastro-ileal anastomosis, two participants had wound
infections and one had a wound hematoma (Foschi et al., 2018). All surgical complications were
cared for and cured without further complications (Foschi et al., 2018).
Foschi et al. (2018) found that while there are complications to surgical procedures, IIDD-SG showed no major complications in this study and was more effective than traditional
medical management of type two diabetes in obese patients with the added benefit of
cardiovascular disease risk factor reduction.
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Reges et al. (2018) performed a retrospective cohort study on an Israeli integrated health
fund, Clalit Health Service, with patients who had bariatric surgery performed between 20052014 with at least one year of follow up to evaluate if non-surgical care or surgical care of obese
patients resulted in a higher mortality. Each surgical participant was matched to a non-surgical
participant based on certain demographics. However, each patient is an individual, and not all
demographics could be accounted for in the matching process. Ultimately, this leads to imperfect
matches. Additionally, due to the length of study and retrospective nature, not all surgeries were
performed at the same time and thus a head to head comparison cannot be made and surgical
advances are not accounted for. The previous limitation to the study can also be viewed as a
strength as surgical advances are generally beneficial. In addition, due to the population number,
Reges et al. (2018) findings can be viewed as universal regardless of the single institution bias.
Reges et al. (2018) used various inclusion and exclusion criteria resulting in a population
of study of 33540, 5490 surgical and 25155 non-surgical. The bariatric surgeries included in this
study were laparoscopic banding (n=3635), RYGB (n=1388), and laparoscopic sleeve
gastrectomy (3362) (Reges et al., 2018).
R version 3.4.0 64-bit was used for all analyses (Reges et al., 2018). Unpaired t tests,
Mann-Whitney U tests, χ2 tests, standard deviations, medians and interquartile ranges were all
used to evaluate the data obtained (Reges et al., 2018). Stratified Cox proportional hazards
regressions with multiple matched pairs (3:1) and 95% confidence intervals were used to
evaluate the association of mortality between the surgical and non-surgical cases (Reges et al.,
2018). One hundred and five deaths were recorded in the surgical patients: 61 laparoscopic
banding, 18 RYGB, and 26 SG. 583 deaths were recorded in the non-surgical group (Reges et
al., 2018). From this data an absolute difference was calculated to be 2.51 (95% CI, 1.86-3.15)
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fewer deaths/1000 person-years in the surgical vs nonsurgical group (Reges et al., 2018).
Adjusted hazard ratios were also recorded between the specific surgical and non-surgical groups
resulting in 2.01 (95% CI, 1.50-2.69) for laparoscopic banding, 2.65 (95% CI, 1.55-4.52) for
Roux-en-Y, and 1.60 (95% CI, 1.02-2.51) for laparoscopic sleeve gastrectomy (Reges et al.,
2018). Overall, the mortality rate was 1.3% among all surgical patients compared to 2.3% of
non-surgical patients over an average of 4.5 years (Reges et al., 2018).
Thus, the above data revealed that there is a lower mortality rate associated with
laparoscopic banding, RYGB, and laparoscopic sleeve gastrectomy than non-surgical obesity
treatments. Therefore, the surgery may be beneficial to qualified patients.
Lifestyle intervention results.
A methodological observational longitudinal cohort study design was done by Alter et al.
(2012) to evaluate the cumulative health system expenditures and health outcomes associated
with obesity in the middle-aged individuals for 11.5 years when at study inception: did not have
cardiovascular disease, were less than 65 years of age, and were not underweight (BMI >18.5
kg/m2). There appears to be no selection bias with obtaining the population of study as all
Canadian provinces were included. However, the inclusion criteria included only individuals that
were less than 65 years of age, so the cumulative health system expenditures and health
outcomes could possibly be greater at a later age as the body begins to fail. Additional
limitations include: propensity scores were unable to be matched to unmeasured risks and this
may have contributed to patient outcome, BMI and physical activity were self-reported and
therefore may not be truthful or exact, not all health care costs were equally represented in the
study such as medical laboratory tests and diagnostic imaging. Finally, another limitation is that
ethnic minorities were under represented. However, the strength of this study was its ability to
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match obese individuals to normal weight individuals of equal risk and follow their health
journey for an extended period. Also, a population of 19,664 is able to gain significant evidence
due to the mass of data that can be obtained.
The population in this observational study by Alter et al. (2012) was obtained via random
dialing of the Ontario Health Survey as part of the 1996/1997 National Population Health Survey
to all Canadian provinces. Information was obtained regarding household health care utilization,
chronic health problems, social characteristics, and individual and cumulative income levels for
all inhabitants (Alter et al., 2012). The participants were then sorted into low income,
intermediate income and high income, if the household made less than $30,000; $30,000$49,999; or greater than $50,000 respectively (Alter et al., 2012). Additionally, participants were
sorted in to Caucasian or non-Caucasian groups by self-reporting, as well as starting BMI
categories (Alter et al., 2012). Obesity was defined as a BMI greater than 30 kg/m2, overweight
was BMI between 25 and 29.9 kg/m2, and normal was defined as a BMI 18.5 to 24.9 kg/m2
(Alter et al., 2012). Other lifestyle factors were obtained from the participants to gather other risk
factors, such as physical activity level, smoking status, and psychological distress (Alter et al.,
2012).
Once the population was selected, 19,664 in total, and sorted, provider visits, cardiac
procedures, hospitalizations, mortality, drug claim costs once older than 65 years old, and
diabetes and hypertension development were followed via a multitude of Canadian health care
system databases and institutes (Alter et al., 2012). The primary outcome of the study was to
evaluate the cumulative Canadian health care expenditure, but the secondary outcome was to
also evaluate mortality, myocardial infarction occurrence, and the development of diabetes or
hypertension during the 11.5 years of the study (Alter et al., 2012).
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Over 11.5 years all primary and specialty provider visits, ER visits, hospitalizations,
invasive cardiac testing, revascularization procedures, and medication costs once individuals
reached the age of 65 years (if less than 65 years old Canada does not pay for medications,
therefore it is more difficult to track cost) were cost adjusted to 2006 Canadian dollars. To
evaluate true obesity associated health care costs each obese individual was matched with a
normal weight individual with similar risk factors such as age, gender, socioeconomic status,
smoking, physical activity, psychosocial stress, and comorbidity such as preexisting diabetes,
hypertension, depression. (Alter et al., 2012). Propensity-score-matched samples were then
created to evaluate the difference in health care cost between normal or healthy weight
individuals and the obese in a 1:1 fashion (Alter et al., 2012). The difference between each
matched pair was then averaged (Alter et al., 2012).
Additionally, risk factor groups were matched with similar groups without risk factors to
evaluate the severity of the risk factor (Alter et al., 2012). Healthy participants with no risk
factors present at the start of the study served as propensity matched controls for any individual
with multiple risk factors (Alter et al., 2012). Greedy nearest-neighbor matching with calipers of
width equal to 0.2 standard deviation of the logit of the propensity score were used to create the
propensity score matched samples (Alter et al., 2012). Statistical significance was defined as
two-tailed p < 0.05, with outcomes compared by paired t-Test and McNemar’s for continuous
and dichotomous variables respectively (Alter et al., 2012).
Alter et al. (2012) ultimately found that obesity by itself is not associated with higher
health care costs as obese individuals without risk factors costed the Canadian health care system
$8,294.67 per person and the propensity matched normal weight individuals costed $7,323.59
per person (p=0.27). However, when an obese individual had one risk factor associated with
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them, their additional cost when compared to their normal weight control rose to $2000, with
risk factors such as smoking and psychological distress costing the most (Alter et al., 2012).
When there were multiple risk factors present and obese individuals increased cost compared to a
normal weight individual rose even higher to $2700 or up to $7000 (Alter et al., 2012). Results
for the development of hypertension or diabetes were similar (Alter et al., 2012). No significant
increase in likelihood of development of either disease in an obese individual until another risk
factor was present (Alter et al., 2012). In addition, obese individual’s mortality rates were 4.6%,
whereas normal weight individuals were 2.1% (p=0.004), and myocardial infarction rates were
6.1% in the obese compared to 2.8% in the normal weight (p=0.001) (Alter et al., 2012).
From the results of Alter et al. (2012) it can be concluded that while obesity is not a
significant risk factor for increased healthcare cost or likelihood of the development of
hypertension or diabetes, it is an important variable when assessing mortality and myocardial
infarction risk, as well as a compounding negative health outcome variable.
Brandt, Clemensen, Nielsen and Søndergaard (2018) performed a qualitative interview
via a collaborative online e-health tool to establish a relationship and monitoring system between
an obese patient and a registered dietician. The aim of this study was to evaluate what makes a
patient’s weight loss efforts successful and if the support of peers and healthcare professionals
through an electronic resource would be useful. Limitations to this study include: the inability to
know if the population of study is familiar enough with technology to use it properly, only
patients who were successful in the previous study were contacted, and during the interviews the
interviewers may have compromised the objectivity of the data through their questioning style.
Additionally, only 10 people were selected for this study, which may hinder the ability to
establish universality for patient success via an online e-health tool. Ultimately, this study is
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important in establishing the importance of continued encouragement through e-health via health
care professionals and internet forums. Five years after this study was performed a survey found
that all participants were still using internet or apps for lifestyle change support.
General practice clinics in southern Denmark were contacted and 10 patients who had
previously participated in a study were selected for interview and possible participation in this
study (Brandt et al., 2018). The initial study these patients had participated in was approximately
5 years ago where a collaborative online health tool was used during a 20-month period to result
in an average of 7.0 kg weight loss (Brandt et al., 2018). After the initial study another study was
done evaluating a more specific group of men and diabetics. Patients were interviewed and the
study found an initial face to face meeting with their health care professional was thought to
improve the establishment of a trusting relationship and therefore may yield better results
(Brandt et al., 2018). The interviews held for this study prior to commencement were held face to
face and focused on patient disease history, experiences when attempting to change lifestyle,
experiences with health care professional and peer support, and experience with e-health tools
(Brandt et al., 2018). Purposive sampling was then done with age, gender and weight loss being
evaluated (Brandt et al., 2018). Three men and seven women, average age of 52, with an average
starting weight of 109 kg and median previous weight loss of 10.5 kg were selected (Brandt et
al., 2018).
An online e-health tool was used by a study participant and a dietician after an initial face
to face meeting (Brandt et al., 2018). The dietician could coach the patient through the tool and
offer support and the patient could share their data with their dietician or hold discussions in
forums with other patients trying to lose weight (Brandt et al., 2018). The goal was to develop a
strong community (Brandt et al., 2018). In this study, one participant did not have a smartphone
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or tablet and instead had his spouse enter his data via the computer (Brandt et al., 2018).
Transcripts were analyzed by thematic analysis and an explorative approach was used for
systemic text consolidation (Brandt et al., 2018). Transcripts were coded, analyzed, shared,
condensed and summarized with overlap identified and researched (Brandt et al., 2018). Data
collection was terminated when new information for themes halted (Brandt et al., 2018).
The most important theme was an honest and trusting relationship with a healthcare
professional to help the participant meet their goals (Brandt et al., 2018). It is also important to
note that 30% of the group initiated a lifestyle change because their healthcare provider voiced
concern about their health (Brandt et al., 2018). Additionally, all participants found it most
effective to continue lifestyle changes when their healthcare professional showed interest in the
participants self-measurements (Brandt et al., 2018). Most participants recognized daily goal
setting was difficult, and it was even more difficult to meet these goals (Brandt et al., 2018). Yet,
these goals were much more manageable than comparative long-term goals. Therefore, this
increased their achievability and helped sustain progress (Brandt et al., 2018). Another theme
among participants was how often they felt tempted to indulge in high calorie foods, and they did
not believe they had the strength to say no or would use illness or another deficit to give in
(Brandt et al., 2018). When participants did give in to cravings, participants noticed that with
even the smallest amount of “cheat” food, their weight went up quickly (Brandt et al., 2018).
Family support, or online support in forums helped patients deal with these temptations and
avoid giving in (Brandt et al., 2018). The ultimate finding of this study was that e-health is an
effective supplement to health care professional’s management of overweight individuals care
(Brandt et al., 2018).
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Kushner (2018) wrote an article about the different weight loss strategies in obesity
management. From this, evaluation of ‘why obesity is difficult to treat’ took place in addition to
how lifestyle factors can be addressed for treatment. This was not a study and was written based
on known data, therefore no limitations or strengths were obtained.
Kushner (2018) found that functional magnetic resonance imaging (fMRI) has shown that
when an obese person is shown the same food images as a non-obese person, their brain has
higher responses in the reward, emotional and cognitive control circuits. Ultimately, The
American Medical Association (AMA) declared obesity a chronic medical condition in 2013
(Kushner, 2018). Lifestyle factors play a role to a certain extent of obesity, and therefore some
patients can be managed with education on diet, nutrition consults, exercise education or classes,
and stress management education (Kushner, 2018). Collaborative care between the provider and
the dietician has been shown to be one of the most useful methods in the lifestyle approach as it
emphasizes the importance of self-management and encourages the patient to get involved with
their own health care (Kushner, 2018). Physical activity is useful for improving cardiovascular
health and increasing the total caloric deficit (Kushner, 2018). One hundred and fifty minutes of
moderate exercise has been shown to prevent weight gain, whereas 250 minutes or greater has
been shown to produce significant weight loss (Kushner, 2018). While it is important to get the
patient involved in their own health care, all treatment plans must be achievable, practical and
goal oriented. The goal of any obese patient is to lose 5-10% of initial weight in 6 months
(Kushner, 2018). However, this may prove to be difficult as many obese patients live in an
obesogenic environment that can cause adaptive biologic processes inhibiting effective weight
loss through hyperactive appetite stimulation centers (Kushner, 2018). If a patient is not able to
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achieve this, and has no contraindication, medical therapy may be the next step in obesity
management.
Li et al. (2018) performed a retrospective cohort study on participants from the Nurses’
Health Study (NHS) from 1980-2014, and the Health Professionals Follow up Study (HPFS)
from 1986-2015. Limitations to this study include: the self-reporting of diet and lifestyle factors
that could result in data misrepresentation, lifestyle factors were equally represented for effect on
mortality and this may not hold true. Finally, baseline comorbid conditions and background
medical therapies were not entirely accounted for. Yet, major strengths of this study were the
long term follow up and the magnitude of participants available for data collection.
The United States is an industrialized country with an advanced technological
infrastructure and strong economic development. When compared to less industrialized nations,
the U.S. has a long-life expectancy, however when compared to countries of equal
industrialization, it is shorter (Li et al., 2018). To date, the U.S. healthcare system spends a
majority of its research and money on disease treatment and new drug discoveries, disregarding
new research on prevention (Li et al., 2018). This study extrapolates on the already known facts
that unhealthy lifestyles are major risk factors for chronic disease and premature death.
Therefore, Li et al. (2018) evaluates common U.S. citizen risk factors and their influence on
mortality and life expectancy.
A population of study was obtained using data from the National Health Service (NHS)
from 1980-2014, and the Health Professionals Follow-up Study (HPFS) from 1986-2015 (Li et
al., 2018). Participants were excluded based on energy intake (females <500 kcal/day or >3500
kcal/day and males <800 kcal/day or >4200 kcal/day), a BMI <18.5 kg/m2, or missing values for
BMI, physical activity, alcohol and smoking (Li et al., 2018). This resulted in a Nurses’ Health
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Study contribution of 78865 participants and a Health Professionals Follow up Study
contribution 44354 participants (Li et al., 2018). Low risk factors were then defined as follows to
be evaluated in biennial questionnaires over the course of 34 years; never smoking, BMI 18.524.9 kg/m2, greater than 30 minutes a day of moderate to vigorous exercise, moderate alcohol
intake (females 5-15 g/day and males 5-30 g/day), and a high-quality diet (diet score in the top
40% of cohort distribution) (Li et al., 2018). If the participant had a low risk factor, they received
a score of one, if they did not, they received a 0 (Li et al., 2018). The sum of the five low risk
factors were then added together to indicate the level of lifestyle healthiness (Li et al., 2018).
Data from the National Health and Nutrition Examination Surveys of 2013-2014 was used to
estimate the geographic distribution of lifestyle scores (Li et al., 2018). The U.S. Center for
Disease Control and Prevention WONDER database was used to derive age of mortality for
Americans (Li et al., 2018). In addition, state vital statistic records, national death index and
reports by families or the postal service were used to further account for mortality (Li et al.,
2018). The association between number of low risk factors and mortality was then made based
on cohort data from the NHS and the HPFS (Li et al., 2018). Life expectancy was then estimated
by these sources in association with the level of lifestyle score (Li et al., 2018).
In the follow up, 42167 participants were lost to mortality (Li et al., 2018). A disease
related mortality breakdown is as follows. In adults with low risk factor scores of five compared
to adults with scores of zero the multivariable adjusted Cox proportional hazard ratio was 0.26
with a 95% confidence interval for cancer mortality (Li et al., 2018). With the same risk
stratification, the multivariable adjusted Cox proportional hazard ratio was 0.35 with a
confidence interval of 95%. (Li et al., 2018) A score of five in the low risk factors yielded
impressive results and can be further distinguished through nonadherence (Li et al., 2018).
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Patients who did not abide by all five of the low risk factors account for 60.7% of all-cause
mortality, 51.7% of cancer mortality, 71.7% of cardiovascular mortality (Li et al., 2018). All
with a confidence intervals of 95% (Li et al., 2018). Life expectancy at age 50 was another 29
years for women and 25.5 years for men if no low risk factors were followed (Li et al., 2018). If
all risk factors were followed, life expectancy at age 50 for women was another 43.1 years and
men another 37.6 years (Li et al., 2018). Again, with a 95% confidence interval (Li et al., 2018).
From the data attained in this study it can be safely asserted that multiple lifestyle factors
affect mortality risk and adopting a healthier lifestyle can increase lifespan (Li et al., 2018). All
the low risk lifestyle factors visited in this study were malleable and thus attainable.
Shaw, Gennat, O’Rourke, and Del Mar (2006) performed an intervention review of
studies that were randomized control trials for the Cochrane Database of Systematic Reviews to
evaluate if exercise is effective in weight loss in obese populations. Studies were only included if
the patients in the trials at baseline were above a normal BMI, and loss less than 15% of
participants to follow up. Limitations of this study included: the lack of long term follow up and
therefore evaluation if physical activity can maintain weight loss and decrease mortality. Another
limitation was that meta-analysis power was reduced as a large number of studies were excluded
due to poor follow up. However, a large number of studies were still able to be evaluated and
result in statistically significant evidence for the promotion of exercise in an overweight or obese
individual. From this, the following study can still be viewed as strong evidence.
Forty-three studies were found and used to establish a Cochrane systematic review (Shaw
et al., 2006). Of the 43 studies used, there were 3476 participants (Shaw et al., 2006). The review
of these studies showed that when exercise and diet were combined, there was greater weight
loss than exercise alone, with a weighted mean difference (WMD) of 1.0 kg and a CI of 95%
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(Shaw et al., 2006). Weight loss was also increased with increased intensity of exercise, WMD
1.5 kg and CI 95% (Shaw et al., 2006). Due to differences between the studies lipid panels, blood
pressure and fasting plasma glucose were not able to be included in the systematic review (Shaw
et al., 2006). However, it was found that exercise alone was able to reduce diastolic blood
pressure by an average of 2 mmHg with a 95% CI (Shaw et al., 2006). Triglycerides were also
shown to be reduced by 0.2 mmol/L with a 95% CI due to exercise alone (Shaw et al., 2006).
Fasting serum glucose was found to have larger decreases with higher intensity workouts with a
0.3 mmol/L reduction and a 95% CI (Shaw et al., 2006). During the systematic review
differences in individual study analyses complicated evaluating all study findings (Shaw et al.,
2006). Ultimately no data was able to be adequately evaluated on adverse effects of physical
activity, quality of life, morbidity, mortality or costs associated (Shaw et al., 2006).
From the data obtained in this Cochrane systematic review, it can be concluded that
exercise is an effective means of reducing cardiovascular disease risk, however exercise
combined with diet improvements offers better results.
Discussion
Alter et al. (2012) examined the cost of obesity on the health care system. Alter et al.
ultimately found that obesity without risk factors is not associated with higher health care costs.
Obese individuals average about $8,294.67 per person and the propensity matched normal
weight individuals costed $7,323.59 per person in the study (p=0.27) (Alter et al., 2012).
However, when an obese individual had one other negative health risk factor, their additional
cost when compared to their normal weight control rose to $2000 (Alter et al., 2012). When
there were multiple risk factors present, obese individuals increased cost compared to a normal
weight individual rose even higher to $2700 or in some cases, up to $7000 (Alter et al., 2012). Of
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the negative health risk factors, smoking and psychological distress cost the most. While being
obese may increase costs on the health care system when associated with additional risk factors,
there is a higher cost to individuals. Obese individual’s mortality rates were 4.6%, whereas
normal weight individuals were 2.1% (p=0.004) (Alter et al., 2012). Myocardial infarction rates
were 6.1% in the obese compared to 2.8% in the normal weight (p=0.001) (Alter et al., 2012).
Therefore, in obese individuals, there is an increased cost on the health care system, and an
increased personal cost to patients. From this, we can see why treating this disease effectively is
so important.
fMRI imaging results found by Kushner (2018) show when an obese individual sees the
same food images as a non-obese person, their brain has higher responses in the reward,
emotional and cognitive control circuits. Thus, making cravings more severe. Collaborative care
between the provider and the dietician to provide education on diet, nutrition consults, exercise
education or classes, and stress management are useful methods in a lifestyle approach to weight
management (Kushner, 2018). This approach emphasizes the importance of self-management
and gets the patient involved with their own health care. Yet, for some this does not work. The
goal of any obese patient is to lose 5-10% of initial weight in 6 months (Kushner, 2018).
However, this may prove to be difficult as many obese patients live in an obesogenic
environment that can caused an adaptive biologic processes inhibiting effective weight loss
through hyperactive appetite stimulation centers (Kushner, 2018). From this biologic change, a
patient who is not able to achieve weight loss in a collaborative medical approach, and has no
contraindication, may need medical therapy as the next step in obesity management.
As the above review of current available literature took place, the valuable use of
pharmacotherapy became apparent. Every study reviewed showed positive benefits for using
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phentermine or orlistat when treating patients for weight loss. However, no study evaluated
solely pharmacotherapy; lifestyle changes were always initiated as well. Costs of treatment were
also briefly evaluated.
For phentermine, Gadde et al. (2011) phentermine 15 mg topiramate 92 mg showed
greater body weight reduction (–10.2 kg absolute change, –9.8% least square mean [95% CI –
10·4 to –9.3]; –8·6% difference [–9.3 to –8.0]; p<0·0001) than phentermine 7.5 mg topiramate
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46 mg dose with a body weight reduction of (–8.1 kg absolute change, –7.8% least squares mean
[95% CI –8.5 to –7.1]; difference –6.6% [–7.4 to –5.8]; p<0.0001). Still, both formulations were
given counselling for diet and lifestyle modification. Ultimately, however, pharmacotherapy with
phentermine achieved overall greater reductions in body weight than lifestyle changes alone, as
can be seen in the below figures. From this, it can be understood that phentermine’s weight loss
effects may improve with increased dosing. Therefore, different levels of BMI may be addressed
in a treatment plan, and pharmacotherapy values may be individualized.
Additionally, Kolotkin, Gadde, Peterson, and Crosby (2015) found that phentermine
topiramate combinations resulted in greater IWQOL-Lite improvements in both EQUIP R 2 =
.417 (p < .0001) compared to placebo and CONQUER compared to placebo R 2 = .326 (p <
.0001). BMI reduction was also found to be significant with phentermine (p<0.0001). This
emphasized that weight loss may be the lone cause for improvement in HRQOL and phentermine
may be used to augment quality improvement.
Weight issues may also stem from problems with food cravings, making it difficult to
lose weight with lifestyle changes alone. Moldovan et al. (2016) performed a highly controlled
study where participants were given Medifast meal replacements and instructed to follow the
Take Shape for Life Optimal Weight 5&1 Plan for weight loss and the Habits of Health program.
There was a placebo group (no medication) and a phentermine group. In both groups, there was a
decrease in cravings reported in the FCI, G‐FCQ‐T, and G‐FCQ‐S. However, the phentermine
group experienced a more substantial fat and sweet craving decrease (p=0.012 and 0.038,
respectively). Participants in the phentermine group also yielded greater weight loss and BMI
reduction with 12.1% weight loss when compared to the placebo group with an 8.8% weight loss
(p=0.028). Specifically, phentermine participants lost 2.1% more fat than the placebo group with
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a p value of 0.019. From this, the study found that Medifast MRS alone can contribute to
statistically significant weight loss and decreased food cravings. However, these results were
augmented when phentermine was added to the weight loss therapy regimen. Additionally,
consideration needs to be taken into patient costs, as Medifast MRS would not be covered by a
patient’s health insurance and therefore would cost an estimated $350.00 per month.
Phentermine may be covered by a patient’s insurance and as the above studies have shown,
allows for weight loss in the absence of Medifast meal replacements, Take Shape for Life
Optimal Weight 5&1 Plan for weight loss and the Habits of Health program. This makes
phentermine a more feasible option for a larger portion of patients.
Moving on to orlistat, Samp, Al-Tahami, Ariffin, Omar, and Rasool (2015) evaluated a 9month study where patients were on orlistat 120 mg three times a day, and then reevaluated the
patients again 4 months after cessation of orlistat by anthropometric parameters. In the ninemonths of orlistat treatment there was statistically significant decreases in total body weight,
BMI, waist circumference, body and visceral fat percentage, total cholesterol, triglyceride,
insulin levels and insulin resistance. After 4 months there was a statistically significant increases
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Al-Tahami, Ariffin, Omar, and Rasool found that orlistat offers health benefits not only while on
treatment, but well after treatment cessation.
Smith et al. (2012) was able to critically evaluate an individual patient on orlistat therapy,
and therefore was able to perform a more intense evaluation of orlistat therapy. The patient was
not on any other medications, other than a daily multivitamin, so all negatives were able to be
attributed to orlistat. The patient was given a one-hour RD taught nutrition class in addition to a
one hour of individual counseling with an RD, and a physical therapist taught exercise class for
an hour before initiation of orlistat therapy. The patient’s adherence was evaluated to be about
69-90% throughout the 6 months of the study. The patient reported numerous side effects, such
as: diarrhea/liquid stool, fatty/oily stool, fecal urgency with control, and gas with discharge.
However, as treatment progressed, side effects decreased. At the end of the sixth months the
patient had achieved a 12.1% weight loss, a fat mass loss of 12.9 kg and a BMI of 27.7 kg/m2,
follow up 2 months after orlistat cessation showed stability of all parameters. Again, showing
how effective orlistat is at promoting weight loss and keeping the weigh off.
A low-calorie diet compared to a low-calorie diet in combination with orlistat 120 mg
taken three times daily was evaluated by Van Baal, Van den Berg, Hoogenveen, Vijgen, and
Engelfriet (2008). Incremental cost-effectiveness ratios (ICERs) were also calculated based on an
interval model of 80 years comparing the two treatment options and the respective treatment
costs and savings due to health benefits. The ultimate ICER that resulted was €58,800 per
Quality adjusted life years (QALY) gained in the orlistat low calorie diet combination and an
ICER of €17,900 per QALY gained for the sole low-calorie diet. Therefore, the conclusion of the
study was that a low-calorie diet without orlistat is a more cost-effective weight loss treatment
plan than in conjunction with orlistat and thus should be the initial treatment of choice.
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Hollywood and Ogden (2016) researched what possible limitations there may be with the
specific pharmacotherapy of orlistat, but a portion of their findings are generalizable. Ten
participants were studied who showed weight gain after 18 months of orlistat drug therapy. As
less than one percent of orlistat is absorbed into the body, there are no systemic side effects
(Kushner, 2018). However, there can be oily anal spotting, flatus with discharge, fecal urgency,
oily stool, and increased defecation, as noted in 10% of patients (Kushner, 2018). Yet, these side
effects are highly related to patient compliance with low fat diet and are experienced early in
drug therapy (Kushner, 2018). As the patient becomes more aware of diet noncompliance side
effects, and what is in the food they are eating, these side effects diminish. Yet, Hollywood and
Ogden (2016) found that GI side effects of orlistat were a big reason that the group of study
discontinued the medication. The study also found that limitations of personal psychology,
physicality, relationships, and individual physiology led to patients to discontinue therapy.
Another major finding of the study was the individual participants thoughts of previous failure
and continued failure due to factors the individual could not control and therefore the weight
gained was not the individuals’ fault. From this, Holly wood and Ogden were able to establish
that patient mental health status and their psychological relationship with obesity may affect their
future weight loss and ability to stick to diet plans, despite negative consequences of
noncompliance. Thus, due to their findings, it may be important to perform mental health status
exams at baseline with obese patients engaging in weight loss treatment.
RYGB and SG are both well researched and relatively safe procedures that may be done
in obese patients to improve weight loss and health status. The review of literature and statistics
show that while surgery is a good option, lifestyle changes are also needed to be made in order to
achieve maximum efficacy.
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Over 20 years Mehaffey et al. (2016) was able to evaluate the effectiveness of RYGB
surgeries and include a minimum of 10 years follow up. Mehaffey found that BMI reduction
peaked at 74% of starting BMI by 24 months and was at 52% at 10 years (both with p <
0.001). Additionally, of all the patients diagnosed with diabetes mellitus type 2 in the study,
57% at 10 years had complete remission of their diabetes. Therefore, Mehaffey found RYGB to
be an effective method of weight loss initially, weight management and reduction of diabetic
status.
So, from the above data we can see that RYGB is effective, but there remains the
question if the same level of success may be achieved with diet and lifestyle changes based on a
multidisciplinary medical management approach. Simonson, Halperin, Foster, Vernon, and
Goldfine (2018) followed their study participants for 3 years post RYGB. Comparing RYGB to
multidisciplinary medical management approach, RYGB showed better results. Specifically,
Simonson found that there was increased weight loss (mean −24.9 kg [95% CI −29.5, −20.4] vs.
−5.2 [−10.3, −0.2]; p < 0.001) and lower HbA1c (−1.79% [−2.38, −1.20] vs. −0.39% [−1.06,
0.28] [−19.6 mmol/mol {95% CI −26.0, −13.1} vs. −4.3 {−11.6, 3.1}]; p < 0.001). RYGB also
lead to improvements in coronary heart disease and stroke risk factors (p < 0.05 to p< 0.01) and
the impact of weight on quality of life (p< 0.001), whereas the multidisciplinary medical
management approach did not. Additionally, Blanco, Funes, Giambartolomei, Menzo,
Szomstein, and Rosenthal (2018) found that RYGB, SG and other weight loss directed surgeries
may lead to a reduction of cardiovascular event risk. An estimated BMI loss post-surgery was
66.51% in females and 60.29% in males, which led to an ASCVD risk decrease (Blanco, 2018).
Female’s ASCVD risk dropped by 35.33% 12 months post operation and males dropped 34.73%.
FRS was also reduced by 32.2% in females and 25.8% in males 12 months post operation.
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Therefore, Simonson and Blanco were able to demonstrate/ that RYGB and other weight loss
surgeries are more effective than the traditional approach of team management and can improve
a wide variety of weight related comorbidities.
To establish post-surgical outcomes regarding patient weight, eating behaviors and
perceived quality of life, Kofman, Lent, and Swencionis (2010) issued a self-reported internet
study. Kofman, Lent, and Swencionis found the mean maximum excess weight loss following
surgery was 81% of starting weight, and 97% of participants achieved weight loss of greater than
50% of starting weight. The maximum postsurgical weight loss occurred at 17.9 months on
average following surgery, with weight regain having a significant correlation with time since
surgery (r = 0.192, p< 0.01). Eighty seven percent of subjects regained an average of 22.6
pounds, with only 11% of participants reporting no weight regain after maximum postsurgical
weight loss. According to the data, a significant relationship was found between participant loss
of control when eating and weight regain r = 0.36 (p< 0.001). Binge eating frequency was also
found to be correlated with weight regain r = 0.24 (p= 0.006). In conjunction, participants also
reported a negative correlation with health related quality of life and weight regain r = −0.35 (p<
0.001), Participants diagnosed with binge eating disorder via the questionnaire also showed
poorer quality of life when compared to their counterparts t[463] = 9.7 (p< 0.001). Thus, this
data was able to show that while obesity may be treated with surgery, it will ultimately not be as
effective if mental health status is not accounted for and treated. Therefore, further evaluation
should be done in these patients, specifically in the mental health component of their obesity.
Moving on to another surgical approach, sleeve gastrectomy, Foschi et al. (2018)
evaluated an ileal interposition with duodenal diversion sleeve gastrectomy (II-DD-SG) to
standard medical care in type two diabetic patients to see which treatment plan is superior. Over
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the course of the study, II-DD-SG’s mean fasting plasma glucose (FPG) fell from 154.6 ± 6.4 to
89.6 ± 2.4 mg/dL and mean HbA1c from 7.7 ± 0.1% to 5.6 ± 0.2% six months after surgery
(Foschi et al., 2018). These results were stable throughout the five years of the study with
p < 0.0001. In 86% of the surgical patients there was complete diabetic remission; 6.6% had
partial remission and only 6.6% were still considered diabetic (Foschi et al., 2018). Only two
patients in the standard medical care group achieved complete remission of diabetes (Foschi et
al., 2018). Also, at the end of the 5-year study, 56% of surgical patients had remission of
cardiovascular risk factors (Foschi et al., 2018). Accordingly, SG may be viewed similar to
RYGB, with increased improvements in weight related comorbidities when compared to a
standard medical approach.
Chopra, Chao, Etkin, Merklinger, Lieb, and Delany (2011) also evaluated SG and its
effects on health status. Chopra was able to find that 84% of their population found improvement
in their diabetic status, 49.99% had improvement in hypertension control, 90% had better asthma
control, 90.74% found improvements in their obstructive sleep apnea symptoms, and 45.92% had
better control of their gastroesophageal reflux disease. Participants’ mean excess weight loss at 6
months was 44.76% from baseline, 55.52% at 12 months, 59.22% at 24 months, and 58.92% at
36 months; thus, showing continued improvement with stability in weight loss 3 years post
operation (Chopra et al., 2011). Consequently, their improved health status would remain stable
as well.
A main concern with weight loss surgery is complications, the most severe of which is
death. Reges et al. (2018) evaluated patients who had bariatric surgery performed with at least
one year of follow up to evaluate if non-surgical care or surgical care of obese patients resulted
in a higher mortality. Laparoscopic banding, RYGB, and SG surgeries were included in the study
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and data. Absolute difference was calculated to be 2.51 (95% CI, 1.86-3.15) fewer deaths/1000
person-years in the surgical vs nonsurgical group (Reges et al., 2018). Adjusted hazard ratios
were also recorded between the specific surgical and non-surgical groups resulting in 2.01 (95%
CI, 1.50-2.69) for laparoscopic banding, 2.65 (95% CI, 1.55-4.52) for Roux-en-Y, and 1.60 (95%
CI, 1.02-2.51) for laparoscopic sleeve gastrectomy (Reges et al., 2018). Overall, the mortality
rate was 1.3% among all surgical patients compared to 2.3% of non-surgical patients over an
average of 4.5 years (Reges et al., 2018). Thus, it can be asserted that while surgery may come
with risks, surgery for treatment of weight loss is still safer than no medical intervention and
failed lifestyle attempts. The reason behind this has not been established, but from the above
data, possible explanations to the mortality reduction may be due to the increased weight loss
and reduction of comorbidities.
So far, this discussion has been based on what can be done with pharmacotherapy and
surgery. However, as we have seen with the above data, this does not mean absolute success.
Therefore, there is still a missing piece to the treatment of obesity. Brandt, Clemensen, Nielsen,
and Søndergaard (2018) researched how failed weight loss attempts can be avoided according to
patients. that Brandt found that an honest and trusting relationship with a healthcare professional
to help the participant meet their goals was important, as 30% of participants initiated a lifestyle
change because their healthcare provider voiced concern about their health. Additionally, all
participants found it most effective to continue lifestyle changes when their healthcare
professional showed interest in the participants self-measurements (Brandt et al., 2018). Other
than having health care professionals noting there is a problem and following up on it,
participants recognized goal setting as difficult. A patient who is a 100 pounds overweight and
sets a goal to lose 100 pounds seems unachievable when viewed in a big picture. Yet, when a
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patient was able to create smaller daily goals this increased success rates as a patient saw them as
more manageable (Brandt et al., 2018). Daily goals helped patients achieve their goals more
often, but they still struggled with temptation. Participants in the study constantly thought about
how in previous weight loss attempts they have been unsuccessful, so why would this be any
different (Brandt et al., 2018)? They also struggled to say no to temptation, because they
believed a little wouldn’t hurt, or that they deserved a treat because they had been so good
(Brandt et al., 2018). When this occurred, participants noticed that with even the smallest amount
of “cheat” food, their weight went up quickly (Brandt et al., 2018). Family support, or online
support in forums helped patients deal with these temptations and avoid giving in (Brandt et al.,
2018). Thus, Brandt was able to conclude that weight loss is a complex issue and patients are
most successful with continued support by family, friends, forums and health care professionals.
While Alter et al. (2012) examined the costs of obesity to the health care system and to
the individual, Li et al. (2018) evaluated the most common U.S. citizen risk factors and their
influence on mortality and life expectancy more concretely as she included normal weight
individuals. Li found that in adults with low risk factor scores of five compared to adults with
scores of zero the multivariable adjusted Cox proportional hazard ratio was 0.26 with a 95%
confidence interval for cancer mortality. With the same risk stratification, the multivariable
adjusted Cox proportional hazard ratio was 0.35 and a confidence interval of 95%. A score of
five in the low risk factors yielded impressive results and can be further distinguished through
nonadherence. Patients who did not abide by all five of the low risk factors account for 60.7% of
all-cause mortality, 51.7% of cancer mortality, 71.7% of cardiovascular mortality. All with a
confidence intervals of 95%. Life expectancy at age 50 was another 29 years for women and 25.5
years for men if no low risk factors were followed. If all risk factors were followed, life
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expectancy at age 50 for women was another 43.1 years and men another 37.6 years. Again, with
a 95% confidence interval. Thus, from Li’s findings, it can be asserted that while it is important
to lose weight and keep it off to avoid negative health consequences, it is also important to adopt
low risk factors and a health lifestyle. This further extrapolates the idea that none of the above
researched weight loss methods will be completely effective when tried alone. A patient needs to
make a lifestyle change, regardless of the medical therapy being used to augment results.
Shaw, Gennat, O’Rourke, and Del Mar (2006) of Cochrane systematic review found that
exercise and diet combined, produced greater weight loss than exercise alone, with a weighted
mean difference (WMD) of 1.0 kg and a confidence interval (CI) of 95%. Weight loss was also
increased with increased intensity of exercise, WMD 1.5 kg and CI 95% (Shaw et al., 2006).
Exercise also reduced diastolic blood pressure by an average of 2 mmHg with a 95% CI, reduced
triglycerides by 0.2 mmol/L with a 95% CI, and fasting serum glucose was found to have higher
decreases with higher intensity workouts with a 0.3 mmol/L reduction and a 95% CI (Shaw et
al., 2006). Kushner also found that exercise is useful for improving cardiovascular health and
increasing the total caloric deficit with 150 minutes of moderate exercise preventing weight gain,
and 250 minutes or greater producing significant weight loss. Therefore, exercise is a crucial part
of the lifestyle change process that should be implemented with all able-bodied patients.
In conclusion, pharmacotherapies such as phentermine and orlistat, and weight loss
surgeries such as gastric bypass and sleeve gastrectomy are valuable tools to treat obesity. They
show increased weight loss results, and this helps patients to continue their weight loss efforts.
However, all medical therapies come with risks. Therefore, all patients should be evaluated prior
to starting any pharmacotherapy or surgical treatment. Additionally, weight loss will not be
effective at reducing patient health risks without the adoption of lifestyle changes. Thus, in
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addition to evaluating for health contraindications, patients should be educated on lifestyle
changes and show that they have incorporated these into their life before medical therapies
should be initiated. As a clinician, it is imperative that they provide support resources for the
patient’s weight loss journey with extensive follow up to encourage continued efforts. With these
efforts on the patient and clinician’s behalf, it may be possible to increase success rates in the
treatment of obesity.
Applicability to Clinical Practice
With the information provided in this systematic literature review, the clinician should be
better able to address obese patient’s treatment plans and give valuable information to the patient
regarding their long-term weight loss outcomes with each method provided. Encouraging
patients to work on diet and exercise for weight loss should be integral to every treatment plan.
However, if the patient does not exhibit results from this method, pharmacological or surgical
therapies should be tried based on the patient’s individual health status, comorbidities, and
benefit to risk ratios.
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